{"classes":[{"categories":[{"measurements":[{"comment":"Median overall survival was not reached at study completion.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Overall survival is defined as the time from protocol therapy initiation to death or date last known alive","dispersionType":"95% Confidence Interval","groups":[{"description":"* Cycles 1-9\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n  * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle\n* Cycle 10-24\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n* Supportive measures consistent with optimal patient care may be given throughout the study\n\nIxazomib: Oral, proteasome inhibitor\n\nLenalidomide: Oral, immunomodulatory agent\n\nDexamethasone: Oral, steroid","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from protocol therapy initiation to death or date last known alive, or up to 60 months post initiation of treatment","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"years"}